From the FDA Drug Label
Table 24 28-Day All-cause Mortality by Baseline Pathogen from the Phase 3 HABP/VABP Trial, micro-ITT Population Aerobic Gram-negative group or pathogenAVYCAZa n/N (%)Meropenemb n/N (%) ... Serratia marcescens0/15 (0)0/13 (0)
Table 25. Clinical Cure Rates at TOC by Baseline Pathogen from the Phase 3 HABP/VABP Trial, micro-ITT Population Aerobic Gram-negative group or pathogenAVYCAZa n/N (%)Meropenemb n/N (%) ... Serratia marcescens11/15 (73.3)12/13 (92.3)
Ceftazidime-Avibactam est efficace contre Serratia marcescens, avec un taux de guérison clinique de 73,3% et un taux de mortalité de 0% dans les essais cliniques 1.
- Les résultats montrent que 11/15 patients infectés par Serratia marcescens ont été guéris avec Ceftazidime-Avibactam.
- Il est important de noter que ces résultats sont basés sur une population spécifique et que l'efficacité du traitement peut varier en fonction de facteurs tels que la sensibilité de la bactérie et la gravité de l'infection.
From the Research
Ceftazidime-avibactam is effective against Serratia marcescens infections, as evidenced by a recent study published in 2021 2. This combination antibiotic pairs ceftazidime, a third-generation cephalosporin, with avibactam, a beta-lactamase inhibitor that helps overcome certain resistance mechanisms. Serratia marcescens is a gram-negative bacterium that can cause various infections, including urinary tract infections, pneumonia, and bloodstream infections. While S. marcescens can develop resistance to many antibiotics, ceftazidime-avibactam typically maintains good activity against it, including against some strains that produce extended-spectrum beta-lactamases (ESBLs). The standard dosing for adults with normal renal function is typically 2.5 grams (2 g ceftazidime and 0.5 g avibactam) administered intravenously every 8 hours, as supported by earlier studies 3, 4, 5, 6. However, dose adjustments are necessary for patients with renal impairment. Before initiating treatment, it's essential to confirm susceptibility through culture and sensitivity testing, as resistance patterns can vary. This combination is usually reserved for serious infections or cases where other antibiotics have failed, to preserve its effectiveness against resistant organisms. Key points to consider when using ceftazidime-avibactam include:
- Its effectiveness against Serratia marcescens, including strains with ESBLs
- The importance of susceptibility testing to guide treatment
- The need for dose adjustments in patients with renal impairment
- The potential for ceftazidime-avibactam to be used in combination with other antibiotics for polymicrobial infections
- The requirement for careful stewardship to preserve the effectiveness of this combination against resistant organisms, as highlighted in the 2021 study 2.